Panbela announces poster presentation at the endocrine society meeting: polyamine inhibition and Β-cell preservation in recent onset type 1 diabetes

Minneapolis, june 26, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for cpp-1x (also known as Α-difluoromethylornithine (dfmo) or eflornithine) in recent onset type 1 diabetes at the endocrine society meeting, which was held june 15-18, 2023. the work reflects the company's ongoing collaboration with indiana university (iu) school of medicine.
PBLA Ratings Summary
PBLA Quant Ranking